aripiprazole / Generic mfg. - LARVOL DELTA

Efficacy and safety of pharmacological treatments in borderline personality disorder: A systematic review and network meta-analysis. (PubMed, Mol Psychiatry) - "Topiramate (200-250 mg/day, 8-10 weeks), lamotrigine (50-200 mg/day, 8 weeks), and aripiprazole (15 mg/day, 8 weeks) most effectively reduced hostility, aggressiveness, and anger, and improved anger control. Carbamazepine (200-1200 mg/ day, 6 weeks) and asenapine (5-10 mg/day, 12 weeks) improved impulsivity and emotional dysregulation, respectively...Conversely, alprazolam, methylphenidate, haloperidol, and valproate had only low-certainty evidence in unselected BPD samples and should not be prioritised. Prescription should be limited to specific, individualised indications, such as panic, comorbid ADHD, or transient psychotic features, following cautious clinical appraisal."

Journal • Retrospective data • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Borderline Personality Disorder • CNS Disorders • Mood Disorders • Personality Disorder • Psychiatry

Trends in Atypical Antipsychotic Use Among Children and Adolescents With Depressive Disorders in Korea. (PubMed, J Korean Med Sci) - "The use of AAPs has progressively increased among Korean children and adolescents with depressive disorders, particularly among those with psychiatric comorbidities. Further studies are needed to establish safer and more evidence-based AAP treatments for depressive disorders in children and adolescents."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Recent Advances in Pharmacological Management of Autism: A Narrative Review. (PubMed, Cureus) - "Medications, including US Food and Drug Administration (FDA)‑approved antipsychotics such as risperidone and aripiprazole, are used to manage comorbid irritability and aggression, stimulants and non‑stimulants (e.g., methylphenidate, atomoxetine, clonidine, guanfacine) to treat ADHD-like symptoms, and melatonin for sleep disturbances. Other off‑label agents like selective serotonin reuptake inhibitor (SSRIs) for anxiety/obsessive compulsive disorder (OCD), anticonvulsants or mood stabilizers for mood dysregulation. Emerging compounds such as intranasal oxytocin and N‑acetylcysteine are under investigation but have not yet been formally approved. The future of ASD care hinges on the development of objective, biologically based diagnostic tools ranging from EEG and neuroimaging biomarkers to proteomic and metabolomic panels that could enable early, precise identification and guide personalized treatment strategies."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Depression • Epilepsy • Genetic Disorders • Immunology • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry • Sleep Disorder

Levels of aripiprazole in the blood with an injection of aripiprazole administered once every two months: a plain language summary of publication. (PubMed, Ther Adv Psychopharmacol) - "They also helped inform the guidance that doctors follow when they prescribe the drug to their patients. The availability of aripiprazole once every 2 months may make treatment easier, and help people stick to their treatment over time."

Journal • Review • Bipolar Disorder • CNS Disorders • Psychiatry • Schizophrenia

Two-injection start regimen of long-acting aripiprazole for bipolar disorder: tips and tricks for better efficacy and tolerability. (PubMed, Front Psychiatry) - "Both regimens had tolerable side effects, with no life-threatening issues. This study highlights the efficacy and reliability of the TIS regimen in treating BD episodes, potentially facilitating faster clinical recovery by reducing the need for prolonged oral supplementation."

Journal • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Persistent Tremor in Bipolar Disorder: A Case Report of Idiopathic Parkinson's Disease Superimposed on Lithium and Antipsychotic Effects. (PubMed, Case Rep Psychiatry) - "Management included discontinuing lithium, switching aripiprazole to quetiapine to limit motor worsening, and starting carbidopa-levodopa...When parkinsonian signs are atypical or persist after medication changes, consider idiopathic PD rather than attributing symptoms to side effects. Care is best delivered through close collaboration between psychiatry and neurology to balance dopaminergic therapy with mood stabilization."

Journal • Bipolar Disorder • CNS Disorders • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Age- and Sex-Specific Incidence Trends of Eating Disorders in South Korea: Insights From a Decade of National Health Insurance Data (2012-2021). (PubMed, Int J Eat Disord) - "The findings show distinct age- and sex-specific patterns in eating disorder incidence, underscoring the need for a tailored approach. Worldwide differences may offer etiological insights. A limitation is the aggregation of eating disorder subtypes."

Journal • Reimbursement • US reimbursement • CNS Disorders • Mood Disorders • Psychiatry

Use of antipsychotics in children and adolescents in Spain, 2015-2023: a real-world, population-based study. (PubMed, Span J Psychiatry Ment Health) - "AP prescriptions and patients treated among Spanish youth increased significantly between 2015 and 2023, with notable differences by age and sex. While total CED rose, treatment intensity per patient remained relatively stable. Future studies should investigate the clinical indications for these prescriptions as well as the outcomes associated with AP use in children and adolescents."

Journal • Real-world evidence • CNS Disorders

Third-Generation Antipsychotics as Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: A Narrative Review of Efficacy and Tolerability. (PubMed, Biomedicines) - "Two cohort studies were included on brexpiprazole, with no active or placebo comparator. The current state of evidence supports the clinical utility of TGAs, particularly aripiprazole, in augmenting SRI treatment in patients with refractory OCD. Evidence regarding cariprazine and lumateperone is scarce, but still contributes to the discussion on the use of TGAs in OCD."

Journal • CNS Disorders • Mental Retardation • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry

Memantine Use in Prolonged Cognitive Sequalae in Pediatric Anti-N-methyl-D-aspartate Receptor Encephalitis: A Three-year Follow-up Case Report and Brief Review. (PubMed, Clin Psychopharmacol Neurosci) - "The patient received immunotherapy including intravenous methylprednisolone, intravenous immunoglobulin, and rituximab, as well as concurrent psychotropics, including valproate and olanzapine/aripiprazole. While 20 mg/day dose of memantine was administering during 6 months, marked improvement was observed in her verbal fluency, academic functioning, and social engagement, that may be associated with post-acute initiation of memantine alongside conventional treatments. This case highlights the evolving understanding of post-autoimmune cognitive rehabilitation and discusses current evidence and theoretical rationale supporting memantine use in complementary treatment of prolonged cognitive dysfunction in the pediatric anti-NMDAR encephalitis."

Journal • Cataplexy • CNS Disorders • Cognitive Disorders • Immunology • Pediatrics • Psychiatry

Multidisciplinary diagnosis and treatment of iatrogenic Cushing syndrome in a patient with obsessive-compulsive disorder. (PubMed, Endocrinol Diabetes Metab Case Rep) - "After the appearance of oral ulcers, the patient uncontrollably used a large amount of chlorhexidine dexamethasone membranes, resulting in iatrogenic Cushing syndrome. The fatty liver and abnormal liver function associated with Cushing syndrome led to the discontinuation of fluvoxamine and aripiprazole for obsessive-compulsive disorder...Multidisciplinary diagnosis and treatment in general hospitals are advantageous or even the only option for improving the prognosis of comorbid mental disorders and somatic diseases. Consultation liaison with psychiatry should be strengthened in general hospitals, especially in the diagnosis and treatment of diseases that are often complicated with psychological symptoms, such as in the endocrinology department."

Journal • CNS Disorders • Cushing’s Disease • Endocrine Disorders • Mental Retardation • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry • Tic Disorders • Tourette Syndrome

Pharmacologic treatment of tics and Gilles de la Tourette syndrome. (PubMed, Handb Clin Neurol) - "The strongest evidence supports the use of dopamine receptor antagonists, particularly atypical antipsychotics such as aripiprazole and risperidone. However, other agents - including α-2 adrenergic agonists, vesicular monoamine transporter 2 inhibitors, and topiramate - also play an important role in treatment strategies. Pharmacologic management of GTS should be individualized, taking into account symptom severity, functional impact, and the risk-benefit profile of each therapeutic option."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Mood Disorders • Movement Disorders • Obsessive-Compulsive Disorder • Psychiatry • Tourette Syndrome

Subchronic Exposure to Aripiprazole Subtly Impacts on Rodents' Sperm Quality and Fertility. (PubMed, Basic Clin Pharmacol Toxicol) - "Fertility test was reduced at a dose of 6 mg/kg. These findings suggest that although aripiprazole is effective in treating mental disorders, it may have subtle adverse effects on reproduction, especially on sperm quality and fertility, raising concerns about its indiscriminate use at doses higher than those tested."

Journal • Preclinical • CNS Disorders • Depression • Mental Retardation • Psychiatry • Schizophrenia

A Multicentre, 4-Year Mirror-Image Study Comparing the Effectiveness of Long-Acting Injectable Antipsychotics in the Treatment of Bipolar Disorder: Results From the LAICO Study. (PubMed, Bipolar Disord) - "Study findings suggest that long-acting antipsychotics such as A1M, PP1M, and particularly PP3M are associated with high retention and lower hospitalisation rates after 2 years of treatment in patients with BD."

Clinical • Journal • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

Olanzapine in the treatment of schizophrenia in adolescents - mechanisms of action and therapeutic efficacy. (PubMed, Psychiatr Pol) - "Olanzapine is effective in adolescent psychosis and mania but carries substantial metabolic liability. Given no clear efficacy advantage over other SGAs, it is best positioned as a second-line agent in youth, with preference for monotherapy, cautious dosing, and stringent metabolic monitoring. Evidence for benefits on negative and cognitive symptoms in adolescents remains limited."

Journal • Review • Bipolar Disorder • CNS Disorders • Depression • Dyslipidemia • Metabolic Disorders • Mood Disorders • Pediatrics • Psychiatry • Schizophrenia

Aripiprazole advances delayed sleep-wake rhythm in methamphetamine-treated mice. (PubMed, Chronobiol Int) - "This entrainment was also accompanied by changes in sleep architecture. These findings brought insights into the mechanism how APZ acts on patients with CRSWD, especially with internal desynchronization."

Journal • Preclinical • Sleep Disorder • Sleep Wake Cycle Disorder

STAMD: Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) (clinicaltrials.gov) - P1/2 | N=520 | Recruiting | Sponsor: First Affiliated Hospital of Chongqing Medical University | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry

Establishment of PK/PD Model for Aripiprazole in the Elderly Population and Exploration of Individualized Medication (ChiCTR) - P=N/A | N=24 | Not yet recruiting | Sponsor: Hangzhou First People's Hospital; Hangzhou First People's Hospital

New trial • CNS Disorders • Psychiatry • Schizophrenia

A Randomized Controlled Trial of Brexpiprazole versus Aripiprazole in the Treatment of Major Depressive Disorder with Psychotic Symptoms in Adolescents (ChiCTR) - P=N/A | N=80 | Not yet recruiting | Sponsor: Shandong mental health center; Shandong mental health center

New trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Comparison of Typical and Atypical Long-Acting Antipsychotics in a Real-World Sample in terms of Treatment Adherence and Factors Influencing Treatment Choice: A One-Year Follow-Up Study. (PubMed, Noro Psikiyatr Ars) - "Adherence was particularly higher with long-acting (LA) aripiprazole and LA paliperidone compared to the other three LAIs (haloperidol, risperidone, and zuclopenthixol) (p<0.05)...Adherence to LAIs administered every four weeks was higher than those administered every two weeks (p=0.014). For patients expected to face challenges with adherence to LAIs, second-generation agents with longer administration intervals may be preferred."

Journal • Real-world evidence • Bipolar Disorder • CNS Disorders • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia

Comparison of In Vitro Metrics With Real-World Risk of Drug-Induced Parkinsonism Due to Antipsychotic Drugs: Retrospective Cohort Study. (PubMed, JMIR Public Health Surveill) - "Among 44,664 patients from 8 matched cohorts, haloperidol showed the highest DIP risk (HR=4.56, 95% CI 2.29-9.07), whereas aripiprazole exhibited the lowest risk (HR=2.11, 95% CI 1.56-2.86). Integrating receptor-binding kinetics with BBB penetration may provide an in vitro framework that reflects real-world variation in DIP risk among D2R-antagonizing APDs. These findings support the relevance of combining kinetic and central nervous system exposure parameters for early safety evaluation."

Clinical • Journal • Preclinical • Real-world evidence • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease

Antipsychotic Treatment and Longitudinal Body Mass Index Trajectories in Youth with and Without Autism Spectrum Disorder. (PubMed, J Clin Med) - "Risperidone and aripiprazole were the most frequently prescribed antipsychotics. Although antipsychotic treatment was initiated earlier in youth with ASD, no clear difference was observed in the rate of BMI z-score change. Differences in weight trajectories underscore the need for metabolic monitoring in antipsychotic-treated youth."

Journal • Autism Spectrum Disorder • CNS Disorders • Genetic Disorders • Mental Retardation • Psychiatry

A Hypersexuality Subset Behavior Induced by Aripiprazole Overdose in an Antipsychotic Naïve Patient: A Case Report and Review of the Literature. (PubMed, Clin Pract) - "Of interest, one month after discontinuing aripiprazole and switching to paliperidone, all the sexual-related symptoms and impulse control disorders resolved. We suggest stronger communication among the clinical teams involved in the patient's care and screening patients for impulse control disorder prior to the administration of aripiprazole and monitoring them during treatment."

Journal • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • DRD2

Optimizing antipsychotic dosing for relapse prevention in cannabis-induced psychosis: A nationwide cohort study. (PubMed, Psychiatry Res) - "Findings indicate dose-dependent real-world effectiveness of antipsychotics in CIP, with most agents performing best at 0.6-<1.4 DDDs/day. These results support optimizing dosing of oral antipsychotic medications for relapse prevention after CIP to balance efficacy and adverse effects."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Levels of and changes in psychosis symptoms and clinical insight: Exploring the impact of differential antipsychotic mechanisms. (PubMed, Psychiatry Res) - "Symptom reduction is associated with improved insight, with early changes in positive symptoms exerting the fastest effect. Despite symptom improvement, aripiprazole PDA treatment was linked to less insight gain than DA treatment. These preliminary findings warrant further study."

Journal • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia